GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDL BioPharma Inc (NAS:PDLI) » Definitions » Shiller PE Ratio

PDL BioPharma (PDL BioPharma) Shiller PE Ratio : 2.91 (As of Apr. 25, 2024)


View and export this data going back to 1992. Start your Free Trial

What is PDL BioPharma Shiller PE Ratio?

As of today (2024-04-25), PDL BioPharma's current share price is $2.47. PDL BioPharma's E10 for the quarter that ended in Jun. 2020 was $0.85. PDL BioPharma's Shiller PE Ratio for today is 2.91.

The historical rank and industry rank for PDL BioPharma's Shiller PE Ratio or its related term are showing as below:

PDLI's Shiller PE Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 33.335
* Ranked among companies with meaningful Shiller PE Ratio only.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

PDL BioPharma's adjusted earnings per share data for the three months ended in Jun. 2020 was $-0.430. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.85 for the trailing ten years ended in Jun. 2020.

Shiller PE for Stocks: The True Measure of Stock Valuation


PDL BioPharma Shiller PE Ratio Historical Data

The historical data trend for PDL BioPharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDL BioPharma Shiller PE Ratio Chart

PDL BioPharma Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.05 1.50 1.76 1.96 2.57

PDL BioPharma Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.24 1.61 2.57 2.33 3.17

Competitive Comparison of PDL BioPharma's Shiller PE Ratio

For the Biotechnology subindustry, PDL BioPharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDL BioPharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDL BioPharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where PDL BioPharma's Shiller PE Ratio falls into.



PDL BioPharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

PDL BioPharma's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=2.47/0.85
=2.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PDL BioPharma's E10 for the quarter that ended in Jun. 2020 is calculated as:

For example, PDL BioPharma's adjusted earnings per share data for the three months ended in Jun. 2020 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2020 (Change)*Current CPI (Jun. 2020)
=-0.43/108.7673*108.7673
=-0.430

Current CPI (Jun. 2020) = 108.7673.

PDL BioPharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201009 0.240 92.162 0.283
201012 -0.220 92.474 -0.259
201103 0.250 94.283 0.288
201106 0.380 95.235 0.434
201109 0.280 95.727 0.318
201112 0.270 95.213 0.308
201203 0.290 96.783 0.326
201206 0.520 96.819 0.584
201209 0.320 97.633 0.356
201212 0.340 96.871 0.382
201303 0.360 98.209 0.399
201306 0.620 98.518 0.685
201309 0.360 98.790 0.396
201312 0.350 98.326 0.387
201403 0.440 99.695 0.480
201406 0.520 100.560 0.562
201409 0.610 100.428 0.661
201412 0.320 99.070 0.351
201503 0.500 99.621 0.546
201506 0.470 100.684 0.508
201509 0.420 100.392 0.455
201512 0.610 99.792 0.665
201603 0.340 100.470 0.368
201606 0.030 101.688 0.032
201609 0.080 101.861 0.085
201612 -0.060 101.863 -0.064
201703 0.040 102.862 0.042
201706 0.390 103.349 0.410
201709 0.140 104.136 0.146
201712 0.150 104.011 0.157
201803 0.010 105.290 0.010
201806 -0.760 106.317 -0.778
201809 0.180 106.507 0.184
201812 0.110 105.998 0.113
201903 0.050 107.251 0.051
201906 -0.040 108.070 -0.040
201909 -0.160 108.329 -0.161
201912 -0.480 108.420 -0.482
202003 -0.260 108.902 -0.260
202006 -0.430 108.767 -0.430

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PDL BioPharma  (NAS:PDLI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


PDL BioPharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of PDL BioPharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PDL BioPharma (PDL BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
932 Southwood Boulevard, Incline Villiage, NV, USA, 89451
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.
Executives
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
John Peter Mclaughlin director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Dominique Monnet officer: President and CEO C/O ALEXION PHARMACEUTICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Christopher Lewis Stone officer: VP, Gen. Counsel & Secretary 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Alan Lee Bazaar director 9 BEDFORD ROAD, KATONAH NY 10536
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Edward Imbrogno officer: VP Finance, CAO and Acting CFO 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Jill M. Jene officer: VP, Business Development 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Harold E Selick director
Samuel R Saks director 3180 PORTER DRIVE, PALO ALTO CA 94304
Paul W Sandman director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Shlomo Yanai director ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Peter S Garcia officer: Vice President, CFO ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jody S Lindell director 2536 FILLMORE ST., SAN FRANCISCO CA 94115
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010